Policy & Regulation
Ascletis submits two IND applications to US FDA for obesity treatments
7 July 2026 - Integrated biotechnology company Ascletis Pharma Inc (HKEX: 1672) has announced the submission of two Investigational New Drug (IND) applications to the US Food and Drug Administration (...
AbbVie's TEPKINLY (epcoritamab) combination approved in Europe to treat relapsed or refractory follicular lymphoma
7 July 2026 - US pharmaceutical company AbbVie (NYSE:ABBV) announced on Monday that the European Commission has granted marketing authorisation for TEPKINLY (epcoritamab) in combination with lenalidom...
Aurinia initiates PRESERVE Phase 4 study of LUPKYNIS combination therapy in lupus nephritis
6 July 2026 - Biopharmaceutical company Aurinia Pharmaceuticals (NASDAQ: AUPH) declared on Monday that it has initiated the PRESERVE Phase 4, multicentre study evaluating LUPKYNIS in combination with ...
Anixa Biosciences advances ovarian cancer CAR-T trial to highest dose level
...
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
6 July 2026 - The Development Center for Biotechnology (DCB), a research institute in Taiwan, said on Friday that six Taiwanese biomedical startups held more than 100 one-on-one business meetings with...
Brii Bio reports Phase 2 end-of-treatment data in chronic hepatitis B
6 July 2026 - Chinese biotechnology company Brii Biosciences Limited (Brii Bio) (HK:2137) has announced end-of-treatment (EOT) results from its ongoing Phase 2b ENRICH and ENHANCE studies investigatin...